Loading clinical trials...

Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma | Clinical Trials | Clareo Health

RECRUITINGNA

Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma

A Prospective, Randomized, Controlled, Multicenter Study Comparing the Right Versus Left Thoracic Surgical Approaches for Locally Advanced Siewert II Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy

NCT06644352•Cancer Institute and Hospital, Chinese Academy of Medical Sciences

View on ClinicalTrials.gov

Summary

To explore the 5-year overall survival (OS) of right versus left thoracic surgical approaches for patients with locally advanced Siewert II gastroesophageal junction adenocarcinoma treated by neoadjuvant chemotherapy

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Histologically confirmed gastroesophageal adenocarcinoma;
•2. R0 resectable Siewert Ⅱ, cT2-3N0-3M0 (AJCC V8 TNM classification);
•3. Have a performance status of 0 or 1 on the ECOG Performance Scale;
•4. Age 18-80 years old, both men and women;
•5. Estimated survival ≥6 months;
•6. Be willing and able to provide written informed consent/assent for the trial;
•7. Demonstrate adequate organ function ;
•8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 7 days before enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;
•9. Have not received systemic or local treatment for esophageal cancer in the past.

Exclusion Criteria

•1. Have a history of other malignant tumors in the past or at the same time;
•2. Previous upper abdominal surgery (excluding cholecystectomy);
•3. Bleeding, perforation and obstruction requiring emergency surgical treatment;
•4. Severe heart, lung, liver and kidney dysfunction, which the researcher thinks is not suitable for operation;
•5. Hydrothorax and ascites with clinical symptoms need therapeutic puncture or drainage;
•6. Participate in other clinical studies or less than 1 month from the end of the previous clinical study;
•7. Have a history of psychoactive drug abuse, alcoholism or drug abuse;
•8. Be unable or do not agree to bear the inspection and treatment expenses at their own expense;
•9. The researcher thinks that it should be excluded from this study.

Locations (1)

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, China

Key Dates

Start Date

July 1, 2022

Primary Completion Date

July 1, 2027

Completion Date

July 1, 2027

Last Updated

October 16, 2024

Enrollment

236

ESTIMATED participants

Conditions

Siewert Type II Adenocarcinoma of Esophagogastric Junction

Interventions

different thoracic surgical approaches

PROCEDURE

Contacts

Yin Li, MD

CONTACT

+8601087788052 liyin@cicams.ac.cn

A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG

NCT04423354

Esophagogastric Junction AdenocarcinomaSiewert Type II Adenocarcinoma of Esophagogastric Junction

View study

UNKNOWN

Classification of Adenocarcinoma of the Esophagogastric Junction

NCT04151524

Oesophagus CancerBarrett Esophagus+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 16, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma

Inclusion Criteria

Exclusion Criteria

A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG

Classification of Adenocarcinoma of the Esophagogastric Junction

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas